2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2417

Pregnancy Outcomes in Systemic Lupus Erythematous and Pre-Systemic Lupus Erythematous: A Population-Based Cohort Study
Abstract Number: 2418

Awareness of Fertility and Contraception Issues Among Women with Rheumatologic Diseases
Abstract Number: 2419

Needs Assessment and Implementation of a Reproductive Health Intention Screen for Women with Systemic Rheumatic Diseases
Abstract Number: 2420

Pregnancy Outcome and Perinatal Complications of Neonate Born to Mothers with Juvenile Idiopathic Arthritis in Asia
Abstract Number: 2421

Pregnancy Outcomes in Women with Rheumatic Diseases and Thrombophilia Treated in a Multidisciplinary Unit
Abstract Number: 2422

Pregnancy Outcomes in Patients with Interstitial Lung Disease Related to Autoimmune Disease and Sarcoidosis
Abstract Number: 2423

Births to Women with Systemic Lupus Erythematosus Can be Identified Accurately in the Electronic Health Record
Abstract Number: 2424

Bisphosphonates during Pregnancy: A Systematic Review Sayanika Kaur MD Fellow Drexel Rheumatology, Mojdeh Khaamesi MD Resident Internal Medicine Arundathi Jayatilleke MD Program Director Drexel Rheumatology
Abstract Number: 2425

The Impact of Biologic Treatment for Rheumatoid Arthritis Patients Who Hope to Conceive
Abstract Number: 2426

Defining a Standardized Core Data Set for Pregnancy Registers in Rheumatic Diseases – an European Approach
Abstract Number: 2427

Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series
Abstract Number: 2428

Correlation between Antibodies to the Phosphotidylserine/Prothrombin Complex (aPS/PT) and Anti-β2glycoprotein-1-Domain 1 (anti-β2GP1-D1) and Vascular Thrombosis (VT) and/or Pregnancy Morbidity (PM)
Abstract Number: 2429

Long-Term Outcome of Children Born to Mothers with Chronic Arthritis and Exposed to TNF-Inhibitors during Pregnancy: A Case-Control Study
Abstract Number: 2430

Pregnancy in Women with Ankylosing Spondylitis Is Not Associated with Poor Obstetric Outcomes: Analysis of Nationwide Inpatient Sample Database 2003-2011
Abstract Number: 2431

Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].